Is ALHC Stock a Buy as Fast Growth Clashes With Premium Valuation?

Alignment Healthcare, Inc. ALHC is expanding quickly while showing better medical-cost control and higher profitability. Second-quarter 2026 membership and revenues both grew more than 31%, and management raised its full-year outlook.

The central question is whether that operating progress warrants paying steep earnings multiple. Growth remains attractive, but higher-acuity members, heavier second-half spending and limited near-term upside to the $14 price target argue for patience.

ALHC’s Membership Growth Strengthens the Bull Case

Health plan membership increased 31.5% year over year to about 294,100 in the second quarter, exceeding the high end of prior guidance. Revenues rose 31.6% to $1.34 billion as new-member additions and retention supported premium growth.

Management now expects 298,000-301,000 members and revenues of $5.20-$5.23 billion for 2026. Alignment Healthcare also sees room to gain share in existing markets before entering additional states, reducing the need to rely on immediate geographic expansion.

Here's where the consensus estimates for the company's sales currently stand.

Image Source: Zacks Investment Research

Clinical Gains Improve ALHC’s Earnings Potential

Adjusted gross profit advanced 35.3% to $182.9 million, while the adjusted medical benefit ratio improved 40 basis points to 86.3%. Adjusted EBITDA rose 48.4% to $68.1 million, producing a 5.1% margin.

The AVA platform can identify the 10% of members expected to account for nearly 70% of hospital admissions over the following 30 days. More targeted clinical intervention could improve productivity as enrollment grows, while maturing member cohorts provide an additional path to higher gross profit.

ALHC’s Valuation Sends Conflicting Signals

ALHC trades at 0.47X forward 12-month sales, below the sub-industry’s 0.52X and its five-year median of 0.73X. That discount suggests the market has already priced in some concern about the durability of growth and margins.

Image Source: Zacks Investment Research

Earnings-based measures are less forgiving. The stock’s forward price-to-earnings ratio is 68.4, while its enterprise value-to-EBITDA ratio is 53.0. Humana Inc. HUM, which is also pursuing Medicare Advantage membership growth, provides a larger-scale comparison for investors assessing the economics of expansion.

Higher-Acuity Growth Raises ALHC’s Risk

New members carry greater medical complexity than the prior-year intake, raising the execution burden on Care Anywhere teams and provider partners. Management expects a seasonally higher third-quarter medical benefit ratio because of member mix, Part D trends and clinical investments.

Third-quarter adjusted EBITDA guidance of $20-$30 million is well below the second quarter’s $68.1 million. UnitedHealth Group Inc. UNH also highlights medical-cost management and pricing as central issues in health-plan performance, underscoring the broader industry sensitivity to utilization.

ALHC Has the Liquidity to Keep Investing

Alignment ended June with $693.5 million in cash and cash equivalents and $8.3 million in current investments. First-half operating cash flow climbed to $111.4 million from $45.7 million a year earlier.

Funded leverage improved to 2.2X trailing adjusted EBITDA. That liquidity gives the company room to fund technology, clinical hiring, claims infrastructure and 2027 market launches without immediate financing pressure.

ALHC’s Scores Support Holding Rather Than Chasing

The operating case remains constructive, but valuation and second-half execution risk limit the appeal of chasing the shares. The $14 price target is only modestly above the Aug. 5 closing price of $13.68.

ALHC currently carries a Zacks Rank #3 (Hold). Its Growth Score of A and VGM Score of A reflect favorable growth characteristics, while the Value Score of B is broadly supportive. The Momentum Score of D signals weaker near-term price action, making a measured holding stance more consistent than an aggressive new entry.

You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research